Please login to the form below

Not currently logged in
Email:
Password:

IMI appoints new chair of scientific committee

Portugal’s Maria Beatriz da Silva Lima to join EC’s collaborative research group

IMI Maria Beatriz da Silva LimaProf Maria Beatriz da Silva Lima has been elected chair of the Scientific Committee of the Innovative Medicines Initiative (IMI).

Prof da Silva Lima (pictured) of the University of Lisbon in Portugal will lead a 12-strogn committee, which provides strategic scientific advice to the IMI – a public-private partnership between the EC and the industry to improve health innovation in Europe.

The IMI also announced that Prof Markus Perola of Finland's National Institute for Health and Welfare as vice-chair of the Committee.

IMI executive director Michel Goldman said: 'The Scientific Committee represents the voice of the scientific community within IMI, and their input is vital to our success.

“I am looking forward to working with Maria Beatriz da Silva Lima and Markus Perola, and the rest of the committee, to foster open collaboration in pharmaceutical research.'

Prof da Silva Lima described the appointment as a “great honour” and praised the work of the IMI so far, which includes a dementia trials alliance between pharma companies and a research collaboration to discover new antibiotics.

She said: “Thanks to IMI, we have seen an enormous reformulation of the European research environment as well as researchers attitude. This re-thinking of the full drug development process is the most challenging and exciting exercise that I have experienced during my entire working life.

“Finally, there is huge potential to expand the principles underlying IMI to the rest of the world.”

16th January 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Medscape Education Global

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....

Latest intelligence

How ‘Greenwashing’ accusations could delay the very changes its supporters demand
Are shouts of companies ‘greenwashing’ to provide a façade of environmental and ethical respectability causing more harm than good? Or should we call out practices that we believe are papering...
What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...